KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Aquestive Therapeutics (AQST) over the last 8 years, with Q3 2025 value amounting to $110.6 million.

  • Aquestive Therapeutics' Shares Outstanding (Weighted Average) rose 2141.18% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.6 million, marking a year-over-year increase of 2141.18%. This contributed to the annual value of $86.7 million for FY2024, which is 4158.03% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Shares Outstanding (Weighted Average) of $110.6 million as of Q3 2025, which was up 2141.18% from $99.3 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Shares Outstanding (Weighted Average) peaked at $110.6 million during Q3 2025, and registered a low of $35.6 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $64.5 million, with a median of $57.4 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 593.86% in 2021 and then soared by 5851.82% in 2024.
  • Aquestive Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $38.1 million in 2021, then rose by 27.99% to $48.7 million in 2022, then grew by 25.69% to $61.3 million in 2023, then soared by 41.58% to $86.7 million in 2024, then increased by 27.51% to $110.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $110.6 million in Q3 2025, compared to $99.3 million in Q2 2025 and $95.5 million in Q1 2025.